Lirimilast is an effective, selective, and orally active phosphodiesterase-4 (PDE4) inhibitor (IC50: 49 nM). Lirimilast has potently anti-inflammatory properties. Lirimilast can be used for the treatment of asthma or chronic obstructive pulmonary disease.

Lirimilast is reported to be 5-fold more effective than Cilomilast and equipotent with CDP-840, In PDE4 assays, using freshly prepared PDE4 from human PMNL[1].

When compared in a rat model of lung neutrophilic inflammation, Lirimilast is found to be 3-fold more potent than Cilomilast. Since Lirimilast is orally active in the guinea-pig at 3 mg/kg and in primates at 0.1 mg/kg/day it appears to have a good therapeutic ratio [2].

329306-27-6

C17H12Cl2N2O6S

443.26

BAY 19-8004

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years